Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine

References

• Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004;10:296-306
   PubMedGoogle Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Lavallée YJ. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993;54(Suppl. 1):3-8
   PubMedGoogle Scholar
• Boulenger JP, Fournier M, Rosales D, et al. Mixed anxiety and depression: from theory to practice. J Clin Psychiatry 1997;58(Suppl. 8):27-34
   PubMedGoogle Scholar
• Hamilton M. A Rating Scale for Depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxiety features. J Clin Psychiatry 1994;55:50-9
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depression tolerability and efficacy in anxious depression. J Aff Disorder 2000;59:119-26
   PubMed Web of Science ®Google Scholar
• Russell JM, Koran IM, Rush AJ, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;25:131-8
   PubMed Web of Science ®Google Scholar
• Fava M, Rush JA, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus non anxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-51
   PubMed Web of Science ®Google Scholar
• Papakostas GI, McGrath P, Stewart J, et al. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res 2008;161:116-20
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006;7:429-40
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Thase M. Escitalopram in the treatment of major depressive disorders: a metaanalysis. Curr Med Res Opin 2009;25:161-75
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
   PubMed Web of Science ®Google Scholar
• Bandelow B, Andersen H, Dolberg O. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007;24:53-61
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
   PubMed Web of Science ®Google Scholar
• Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. J Clin Psychiatry 2006;67:1428-34
   PubMed Web of Science ®Google Scholar
• ICH. (1996) ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice. Available from: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf. Accessed 6 September, 2009
   Google Scholar
• World Medical Association (WMA). (1964) Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm. Accessed 6 September, 2009
   Google Scholar
• Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1-37
   PubMedGoogle Scholar
• Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD, National Institute of Mental Health
   Google Scholar
• Fava M, Rush J, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J. Psychiatry 2006;51:823-35
   PubMed Web of Science ®Google Scholar
• Nelson JC. Anxious depression and response to treatment. Am J Psychiatry 2008;165:297-9
   PubMed Web of Science ®Google Scholar
• World Health Organisation (WHO). The ICD-10 Classification of Mental Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992
   Google Scholar
• Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
   PubMed Web of Science ®Google Scholar
• Kasper S, Baldwin DS, Larsson Lönn S, et al. Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 2009;19:229-39
   PubMed Web of Science ®Google Scholar
• Kasper S, Sacher J, Klein N, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009;24:119-25
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Hughes M, et al. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorders. Psychiatry Res 2004;126:287-90
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32
   PubMed Web of Science ®Google Scholar
• TLV (The Dental and Pharmaceuticals Benefits Agency). The review of antidepressants. December, 2008. Available online at http://www.tlv.se/Upload/Genomgangen/review-antidepressants.pdf. Accessed 29 October, 2009
   Google Scholar
• Wade AG, Fernández JL, Francois C, et al. Escitalopram and duloxetine in Major Depressive Disorder. A pharmacoeconomic comparison using UK cost data. Pharmacoeconomics 2008;26:969-81
   Google Scholar